Encapsulation of Antifungals in Micelles Protects Candida albicans during Gall-Bladder Infection
Open Access
- 1 February 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 8, 117
Abstract
Candida albicans is a dimorphic fungus that colonises human mucosal surfaces with the potential to cause life-threatening invasive candidiasis. Studies on systemic candidiasis in a murine infection model using in vivo real-time bioluminescence imaging revealed persistence of C. albicans in the gall bladder under antifungal therapy. Preliminary analyses showed that bile conferred resistance against a wide variety of antifungals enabling survival in this cryptic host niche. Here, bile and its components were studied for their ability to reduce antifungal efficacy in order to elucidate the underlying mechanism of protection. While unconjugated bile salts were toxic to C. albicans, taurine or glycine conjugated bile salts were well tolerated and protective against caspofungin and amphotericin B when exceeding their critical micellar concentration (CMC). Microarray experiments indicated that upregulation of genes generally known to mediate antifungal protection is not involved in the protection process. In contrast, rhodamine 6G and Crystal violet in- and efflux experiments indicated encapsulation of antifungals in micelles, thereby reducing their bioavailability. Furthermore, farnesol sensing was abolished in the presence of conjugated bile salts trapping C. albicans cells in the yeast morphology. This suggests that bioavailability of amphiphilic and hydrophobic compounds is reduced in the presence of bile. In contrast, small and hydrophilic molecules such as cycloheximide, flucytosine or sodium azide kept their antifungal properties. We therefore conclude that treatment of gall bladder and bile duct infections is hampered by the ability of bile salts to encapsulate antifungals in micelles. As a consequence, treatment of gall bladder or bile duct infections should favour the use of small hydrophilic drugs that are not solubilised in micelles.Keywords
This publication has 43 references indexed in Scilit:
- Recent insights into Candida albicans biofilm resistance mechanismsCurrent Genetics, 2013
- Bio-relevant media to assess drug permeability: Sodium taurocholate and lecithin combination or crude bile?International Journal of Pharmaceutics, 2012
- Candida tropicalis infection in a term neonate with gall bladder masses and infective endocarditisAsian Pacific Journal of Tropical Medicine, 2012
- The Candida genome database incorporates multiple Candida species: multispecies search and analysis tools with curated gene and protein information for Candida albicans and Candida glabrataNucleic Acids Research, 2011
- Infections in liver transplant recipientsWorld Journal of Hepatology, 2011
- Mechanisms of Membrane Transport of Poorly Soluble Drugs: Role of Micelles in Oral Absorption ProcessesJournal of Pharmaceutical Sciences, 2010
- A Phenotypic Profile of the Candida albicans Regulatory NetworkPLOS Genetics, 2009
- Invasive Fungal InfectionsDrugs, 2009
- Transcriptional Regulation of Carbohydrate Metabolism in the Human Pathogen Candida albicansPLOS Pathogens, 2009
- Oral candidiasisPostgraduate Medical Journal, 2002